J&J Risperdal Consta “non-approvable”
Executive Summary
J&J will discuss FDA concerns about pre-clinical data for injectable long-acting antipsychotic Risperdal Consta (risperidone) following receipt of "non-approvable" letter. J&J filed the NDA Aug. 31, 2001...
You may also be interested in...
J&J Finalizing Risperdal Consta Resubmission; Approval Possible By Year-End
Johnson & Johnson is finalizing its response to a Risperdal Consta "not approvable" letter received from FDA last year
Alkermes Cutbacks Play Well On Wall Street; Biotech Model In Down Market?
Alkermes' August rebound on Wall Street suggests that the less-is-more approach is playing well with investors
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.